Maggie Brant

Maggie Brant serves as a key procurement lead within the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, where she manages complex research-support acquisitions aligned with the agency’s mission to advance scientific understanding of substance use disorders. She oversees the acquisition of specialized scientific equipment, analytical laboratory services, biomanufacturing capabilities, and software solutions that enable cutting-edge neurobiological and behavioral research. Her portfolio emphasizes translating laboratory innovations into clinical and public health applications, requiring deep technical familiarity with research infrastructure and translational science procurement. Brant maintains longstanding relationships with leading academic and research institutions, including The McLean Hospital Corporation, the University of Maryland Baltimore, the University of Miami, the University of Pittsburgh, and the Icahn School of Medicine at Mount Sinai. These partnerships are primarily research-focused, involving contracts for preclinical studies, clinical trial support, data analytics platforms, and specialized instrumentation. Her procurement approach prioritizes collaboration with mission-aligned academic medical centers that possess the infrastructure and expertise to execute high-complexity, federally funded neuroscience research. Her contracting activity reflects a strong preference for open competition, with 96.9% of awards issued without set-aside restrictions, indicating a focus on technical capability over socioeconomic categorization. While small business participation is limited, it is consistently directed toward Total Small Business Set-Asides under FAR 19.5, suggesting targeted support for qualified small firms capable of meeting rigorous scientific requirements. Brant’s procurement focus centers on NAICS 334516 (Analytical Laboratory Instrument Manufacturing) and 325414 (Biological Product Manufacturing), reflecting her emphasis on procuring advanced instrumentation for neuroimaging, drug metabolism analysis, and biologics development. She also regularly acquires services under 513210 (Software Publishers) and 541380 (Testing Laboratories), underscoring her domain expertise in data-driven research tools and quality-controlled analytical services essential to NIDA’s scientific priorities.